J
Jaclyn N. Highland
Researcher at University of Maryland, Baltimore
Publications - 10
Citations - 998
Jaclyn N. Highland is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Hydroxynorketamine & NMDA receptor. The author has an hindex of 7, co-authored 8 publications receiving 568 citations.
Papers
More filters
Journal ArticleDOI
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Panos Zanos,Ruin Moaddel,Patrick J. Morris,Lace M. Riggs,Jaclyn N. Highland,Polymnia Georgiou,Edna F. R. Pereira,Edson X. Albuquerque,Craig J. Thomas,Carlos A. Zarate,Todd D. Gould +10 more
TL;DR: Pharmacological target deconvolution of ketamine and its metabolites will provide insight critical to the development of new pharmacotherapies that possess the desirable clinical effects of ketamines, but limit undesirable side effects.
Journal ArticleDOI
(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions.
Panos Zanos,Jaclyn N. Highland,Brent W. Stewart,Polymnia Georgiou,Carleigh Jenne,Jacqueline Lovett,Patrick J. Morris,Craig J. Thomas,Ruin Moaddel,Carlos A. Zarate,Todd D. Gould,Todd D. Gould +11 more
TL;DR: The findings highlight that (2R,6R)-HNK exerts antidepressant-relevant actions via a mechanism converging with mGlu2 receptor signaling and suggest enhanced cortical gamma oscillations as a marker of target engagement relevant to antidepressant efficacy.
Journal ArticleDOI
A Negative Allosteric Modulator for α5 Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice.
Panos Zanos,Mackenzie E. Nelson,Jaclyn N. Highland,Samuel R. Krimmel,Polymnia Georgiou,Todd D. Gould,Scott M. Thompson +6 more
TL;DR: This article showed that negative allosteric modulators of GABA-A receptors containing α5 subunits (α5 GABA-NAMs) should also promote high-frequency correlated electroencephalogram (EEG) activity and should therefore exert rapid antidepressant responses.
Journal ArticleDOI
(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.
Panos Zanos,Jaclyn N. Highland,Xin Liu,Timothy A. Troppoli,Polymnia Georgiou,Jacqueline Lovett,Patrick J. Morris,Brent W. Stewart,Craig J. Thomas,Scott M. Thompson,Ruin Moaddel,Todd D. Gould +11 more
TL;DR: (R)‐Ketamine (arketamine) may have utility as a rapidly acting antidepressant while (R,S)‐ketamine has lower potency to inhibit NMDA receptors in vitro, and is metabolised to (2R,6R)'s HNK, which may contribute to its antidepressant‐relevant actions.
Journal ArticleDOI
Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications.
Jaclyn N. Highland,Panos Zanos,Lace M. Riggs,Polymnia Georgiou,Sarah M. Clark,Patrick J. Morris,Ruin Moaddel,Craig J. Thomas,Carlos A. Zarate,Edna F. R. Pereira,Todd D. Gould +10 more
TL;DR: A review of the pharmacokinetics and pharmacodynamics of hydroxynorketamines, as well as their behavioral actions, putative mechanisms of action, and potential therapeutic applications can be found in this paper.